Revital Nimri1, Moshe Phillip. 1. aThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva bSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
PURPOSE OF REVIEW: This review describes the latest efforts, challenges, and experience of using automated insulin delivery systems at outpatient settings and home studies. This is an important step in getting recognition of these systems as a routine therapy for patients with type 1 diabetes. RECENT FINDINGS: Almost 3 years elapsed since the first description of closed-loop use outside the protecting environment of the hospital, at a diabetes camp. In this period, several different approaches of closed-loop systems were used at outpatient settings. The low-glucose suspend feature on the pump showed a reduction in the risk of nocturnal hypoglycemia. Closed-loop systems with diverse control algorithms with a single or bihormonal approach showed an improvement in glycemic control. The improvement was demonstrated during the overnight use and during the 24-h use. The outpatient studies with closed-loop systems, especially overnight at home, demonstrated that the current configurations are already safe and efficient for daily use. Technological advancement should undoubtedly lead to even better performance. SUMMARY: Studies using closed-loop systems at patients' home are currently being carried out. The preliminary results of these experiments are encouraging and enhance our confidence in this tool as suitable for use in clinical daily practice.
PURPOSE OF REVIEW: This review describes the latest efforts, challenges, and experience of using automated insulin delivery systems at outpatient settings and home studies. This is an important step in getting recognition of these systems as a routine therapy for patients with type 1 diabetes. RECENT FINDINGS: Almost 3 years elapsed since the first description of closed-loop use outside the protecting environment of the hospital, at a diabetescamp. In this period, several different approaches of closed-loop systems were used at outpatient settings. The low-glucose suspend feature on the pump showed a reduction in the risk of nocturnal hypoglycemia. Closed-loop systems with diverse control algorithms with a single or bihormonal approach showed an improvement in glycemic control. The improvement was demonstrated during the overnight use and during the 24-h use. The outpatient studies with closed-loop systems, especially overnight at home, demonstrated that the current configurations are already safe and efficient for daily use. Technological advancement should undoubtedly lead to even better performance. SUMMARY: Studies using closed-loop systems at patients' home are currently being carried out. The preliminary results of these experiments are encouraging and enhance our confidence in this tool as suitable for use in clinical daily practice.
Authors: Eyal Dassau; Sue A Brown; Ananda Basu; Jordan E Pinsker; Yogish C Kudva; Ravi Gondhalekar; Steve Patek; Dayu Lv; Michele Schiavon; Joon Bok Lee; Chiara Dalla Man; Ling Hinshaw; Kristin Castorino; Ashwini Mallad; Vikash Dadlani; Shelly K McCrady-Spitzer; Molly McElwee-Malloy; Christian A Wakeman; Wendy C Bevier; Paige K Bradley; Boris Kovatchev; Claudio Cobelli; Howard C Zisser; Francis J Doyle Journal: J Clin Endocrinol Metab Date: 2015-07-23 Impact factor: 5.958
Authors: Maria Elena Lunati; Paola Silvia Morpurgo; Antonio Rossi; Alessandra Gandolfi; Irene Cogliati; Andrea Mario Bolla; Laura Plebani; Luciana Vallone; Laura Montefusco; Ida Pastore; Vincenzo Cimino; Sabrina Argenti; Graziella Volpi; Gian Vincenzo Zuccotti; Paolo Fiorina Journal: Front Endocrinol (Lausanne) Date: 2022-04-14 Impact factor: 6.055